Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas

  • Sánchez-Tilló, Ester
  • Pedrosa, Leire
  • Vila, Ingrid
  • Chen, Yongxu
  • Gyorffy, Balázs
  • Sánchez-Moral, Lidia
  • Siles, Laura
  • Lozano, Juan José
  • Esteve-Codina, Anna
  • Darling, Douglas S.
  • Cuatrecasas, Miriam
  • Castells, Antoni
  • Maurel, Joan
  • Postigo, Antonio
Despite being in the same pathway, mutations of KRAS and BRAF in colorectal carcinomas (CRCs) determine distinct progression courses. ZEB1 induces an epithelial-to-mesenchymal transition (EMT) and is associated with worse progression in most carcinomas. Using samples from patients with CRC, mouse models of KrasG12D and BrafV600E CRC, and a Zeb1-deficient mouse, we show that ZEB1 had opposite functions in KRAS- and BRAF-mutant CRCs. In KrasG12D CRCs, ZEB1 was correlated with a worse prognosis and a higher number of larger and undifferentiated (mesenchymal or EMT-like) tumors. Surprisingly, in BrafV600E CRC, ZEB1 was associated with better prognosis; fewer, smaller, and more differentiated (reduced EMT) primary tumors; and fewer metastases. ZEB1 was positively correlated in KRAS-mutant CRC cells and negatively in BRAF-mutant CRC cells with gene signatures for EMT, cell proliferation and survival, and ERK signaling. On a mechanistic level, ZEB1 knockdown in KRAS-mutant CRC cells increased apoptosis and reduced clonogenicity and anchorage-independent growth; the reverse occurred in BRAFV600E CRC cells. ZEB1 is associated with better prognosis and reduced EMT signature in patients harboring BRAF CRCs. These data suggest that ZEB1 can function as a tumor suppressor in BRAF-mutant CRCs, highlighting the importance of considering the KRAS/BRAF mutational background of CRCs in therapeutic strategies targeting ZEB1/EMT., The experimental work in this study was funded by independent grants to EST and AP. Funding for EST came from the Spanish National Institute of Health Carlos III (ISCIII) through the Miguel Servet Program (grant CP13/00200) and the National Plan of Scientific and Technical Research and Innovation Plan 2013-2016 cofinanced by the European Regional Development Fund of the European Union Commission (EUC-ERDF) (grants AES2018 and PI18/00244). Grants to AP that funded independent parts of the study originated from the Spanish Association Against Cancer (AECC; grant PROYE19040POST_001), Olga Torres Foundation (biannual grant A-2019/2020), Catalan Agency for Management of University and Research Grants (AGAUR) (grants 2017-SGR-1174 and 2021-SGR-01328), and the Spanish State Research Agency (AEI) of the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-116338RB-I00) as part of MICINN’s National Scientific and Technical Research and Innovation 2021-2023 Plans, which are cofinanced by the EUC-ERDF. The salaries of both EST and IV were funded by a Miguel Servet contract (reference MS13/00200) and a grant (CPII18/00022) from ISCIII to EST. LP was funded by the AECC (project GCTRA16015SEDA). YC is the recipient of a doctoral scholarship from the China Scholarship Council (202008440322). BG was financed by the 2020-1.1.6-JÖVŐ-2021-00013 and 2020-4.1.1-TKP2020 grants of the Ministry for Innovation and Technology in Hungary. LSM is the recipient of a doctoral scholarship from the University Lecturer Training (FPU) Program (FPU14/06217) of the Spanish Ministry of Universities. AEC’s salary is covered by grant PT17/0009/0019 from ISCIII (MICINN, cofunded by the ERDF) to CNAG-CRG.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation

  • Martinez-Campanario, M. C.
  • Cortés, Marlies
  • Moreno-Lanceta, Alazne
  • Han, Lu
  • Ninfali, Chiara
  • Domínguez, Verónica
  • Andrés-Manzano, María J.
  • Farràs, Marta
  • Esteve-Codina, Anna
  • Enrich, Carlos
  • Díaz-Crespo, Francisco J.
  • Pintado, Belén
  • Escolà-Gil, Joan Carles
  • García de Frutos, Pablo
  • Andrés, Vicente
  • Melgar-Lesmes, Pedro
  • Postigo, Antonio
Accumulation of lipid-laden macrophages within the arterial neointima is a critical step in atherosclerotic plaque formation. Here, we show that reduced levels of the cellular plasticity factor ZEB1 in macrophages increase atherosclerotic plaque formation and the chance of cardiovascular events. Compared to control counterparts (Zeb1 /Apoe ), male mice with Zeb1 ablation in their myeloid cells (Zeb1 /Apoe ) have larger atherosclerotic plaques and higher lipid accumulation in their macrophages due to delayed lipid traffic and deficient cholesterol efflux. Zeb1 /Apoe mice display more pronounced systemic metabolic alterations than Zeb1 /Apoe mice, with higher serum levels of low-density lipoproteins and inflammatory cytokines and larger ectopic fat deposits. Higher lipid accumulation in Zeb1 macrophages is reverted by the exogenous expression of Zeb1 through macrophage-targeted nanoparticles. In vivo administration of these nanoparticles reduces atherosclerotic plaque formation in Zeb1 /Apoe mice. Finally, low ZEB1 expression in human endarterectomies is associated with plaque rupture and cardiovascular events. These results set ZEB1 in macrophages as a potential target in the treatment of atherosclerosis., IDIBAPS is partly funded by the Generalitat of Catalonia’s CERCA Programme. The studywas conducted at the IDIBAPS’ Centre de Recerca Biomèdica Cellex building,which was partly funded by the Cellex Foundation. The different parts of this study were independently funded by grants to A.P. from the Catalan Agency forManagement of University and Research Grants (AGAUR) (2021-SGR- 01328), and Spanish State Research Agency (AEI) (PID2020-116338RBI00) of the Ministry of Science and Innovation (MICINN), as part of the 2021–2023 Plan for Scientific and Technical Research and Innovation (PEICTI), which is co-financed by the European Regional Development Fund (ERDF) of the European Union Commission. A.M.-L. is a recipient of a PhD scholarship from MICINN (FPI Program) (PRE2019-088097). A.E.- C’s salary is covered by grant PT17/0009/0019 from Carlos III Spanish Health Institute (ISCIII, co-funded by the ERDF) to CNAG. CNIC is supported by MCINN, ISCIII, the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/ 10.13039/501100011033). P.M.-L. salary is supported by a fellowship from AEI’s Ramon y Cajal Program (RYC2018-0Z23971-I). L.H. is supported by a PhD scholarship from the China Scholarship Council (202208110041)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inflammatory macrophages reprogram to immunosuppression by reducing mitochondrial translation

  • Cortés, Marlies
  • Brischetto, Agnese
  • Martínez-Campanario, M. C.
  • Ninfali, Chiara
  • Domínguez, Verónica
  • Fernández, Sara
  • Celis, Raquel
  • Esteve-Codina, Anna
  • Lozano, Juan J.
  • Sidorova, Julia
  • Garrabou, Gloria
  • Siegert, Anna-Maria
  • Enrich, Carlos
  • Pintado, Belén
  • Morales-Ruiz, Manuel
  • Castro, Pedro
  • Cañete, Juan D.
  • Postigo, Antonio
Acute inflammation can either resolve through immunosuppression or persist, leading to chronic inflammation. These transitions are driven by distinct molecular and metabolic reprogramming of immune cells. The anti-diabetic drug Metformin inhibits acute and chronic inflammation through mechanisms still not fully understood. Here, we report that the anti-inflammatory and reactive-oxygen-species-inhibiting effects of Metformin depend on the expression of the plasticity factor ZEB1 in macrophages. Using mice lacking Zeb1 in their myeloid cells and human patient samples, we show that ZEB1 plays a dual role, being essential in both initiating and resolving inflammation by inducing macrophages to transition into an immunosuppressed state. ZEB1 mediates these diverging effects in inflammation and immunosuppression by modulating mitochondrial content through activation of autophagy and inhibition of mitochondrial protein translation. During the transition from inflammation to immunosuppression, Metformin mimics the metabolic reprogramming of myeloid cells induced by ZEB1. Mechanistically, in immunosuppression, ZEB1 inhibits amino acid uptake, leading to downregulation of mTORC1 signalling and a decrease in mitochondrial translation in macrophages. These results identify ZEB1 as a driver of myeloid cell metabolic plasticity, suggesting that targeting its expression and function could serve as a strategy to modulate dysregulated inflammation and immunosuppression., The study was conducted at IDIBAPS’ Centre de Recerca Biomèdica Cellex building, which was partly funded by the Cellex Foundation. The different parts of this study were independently funded by grants to AP from the Leo Foundation (LF-OC-19-000166), the Catalan Agency for Management of University and Research Grants (AGAUR) (2017-SGR-1174 and 2021-SGR-01328), and the Spanish State Research Agency (AEI) of the Ministry of Science and Innovation (MICINN) (PID2020-116338RB-I00) as part of MICINN’s National Scientific and Technical Research and Innovation 2021-2023 Plan, which is cofinanced by the European Regional Development Fund (ERDF) of the European Union Commission. AB is a recipient of a PhD scholarship from AGAUR (FI Program, 2021 FI_B 00514), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The adaptive antioxidant response during fasting-induced muscle atrophy is oppositely regulated by ZEB1 and ZEB2

  • Ninfali, Chiara
  • Cortés, Marlies
  • Martínez-Campanario, M. C.
  • Domínguez, Verónica
  • Han, Lu
  • Tobías, Ester
  • Esteve-Codina, Anna
  • Enrich, Carlos
  • Pintado, Belén
  • Garrabou, Gloria
  • Postigo, Antonio
Reactive oxygen species (ROS) serve important homeostatic functions but must be constantly neutralized by an adaptive antioxidant response to prevent supraphysiological levels of ROS from causing oxidative damage to cellular components. Here, we report that the cellular plasticity transcription factors ZEB1 and ZEB2 modulate in opposing directions the adaptive antioxidant response to fasting in skeletal muscle. Using transgenic mice in which Zeb1 or Zeb2 were specifically deleted in skeletal myofibers, we show that in fasted mice, the deletion of Zeb1, but not Zeb2, increased ROS production and that the adaptive antioxidant response to fasting essentially requires ZEB1 and is inhibited by ZEB2. ZEB1 expression increased in fasted muscles and protected them from atrophy; conversely, ZEB2 expression in muscles decreased during fasting and exacerbated muscle atrophy. In fasted muscles, ZEB1 reduces mitochondrial damage and increases mitochondrial respiratory activity; meanwhile, ZEB2 did the opposite. Treatment of fasting mice with Zeb1-deficient myofibers with the antioxidant triterpenoid 1[2-cyano- 3,12- dioxool- eana- 1,9( 11)-dien- 28- oyl] trifluoro-ethylamide (CDDO-TFEA) completely reversed their altered phenotype to that observed in fasted control mice. These results set ZEB factors as potential therapeutic targets to modulate the adaptive antioxidant response in physiopathological conditions and diseases caused by redox imbalance., The different parts of this study were independently funded by grants to A.P. from Duchenne Parent Project Spain (DPPE/01_2018), the Catalan Agency for Management of University and Research Grants (AGAUR) (2021- SGR 01328), and the Spanish State Research Agency (AEI) of the Spanish Ministry of Science and Innovation (PID2020- 116338RB- I00) as part of the 2021- 2023 Plan for Scientific and Technical Research and Innovation (PEICTI), which is co- financed by the European Regional Development Fund of the European Union Commission. L.H. is supported by a PhD scholarship from the China Scholarship Council (202208110041), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas

  • Sánchez-Tilló, Ester
  • Pedrosa, Leire
  • Vila, Ingrid
  • Chen, Yongxu
  • Gyorffy, Balázs
  • Sánchez-Moral, Lidia
  • Siles, Laura
  • Lozano, Juan José
  • Esteve-Codina, Anna
  • Darling, Douglas S.
  • Cuatrecasas, Miriam
  • Castells, Antoni
  • Maurel, Joan
  • Postigo, Antonio
Despite being in the same pathway, mutations of KRAS and BRAF in colorectal carcinomas (CRCs) determine distinct progression courses. ZEB1 induces an epithelial-to-mesenchymal transition (EMT) and is associated with worse progression in most carcinomas. Using samples from patients with CRC, mouse models of KrasG12D and BrafV600E CRC, and a Zeb1-deficient mouse, we show that ZEB1 had opposite functions in KRAS- and BRAF-mutant CRCs. In KrasG12D CRCs, ZEB1 was correlated with a worse prognosis and a higher number of larger and undifferentiated (mesenchymal or EMT-like) tumors. Surprisingly, in BrafV600E CRC, ZEB1 was associated with better prognosis; fewer, smaller, and more differentiated (reduced EMT) primary tumors; and fewer metastases. ZEB1 was positively correlated in KRAS-mutant CRC cells and negatively in BRAF-mutant CRC cells with gene signatures for EMT, cell proliferation and survival, and ERK signaling. On a mechanistic level, ZEB1 knockdown in KRAS-mutant CRC cells increased apoptosis and reduced clonogenicity and anchorage-independent growth; the reverse occurred in BRAFV600E CRC cells. ZEB1 is associated with better prognosis and reduced EMT signature in patients harboring BRAF CRCs. These data suggest that ZEB1 can function as a tumor suppressor in BRAF-mutant CRCs, highlighting the importance of considering the KRAS/BRAF mutational background of CRCs in therapeutic strategies targeting ZEB1/EMT., The experimental work in this study was funded by independent grants to EST and AP. Funding for EST came from the Spanish National Institute of Health Carlos III (ISCIII) through the Miguel Servet Program (grant CP13/00200) and the National Plan of Scientific and Technical Research and Innovation Plan 2013-2016 cofinanced by the European Regional Development Fund of the European Union Commission (EUC-ERDF) (grants AES2018 and PI18/00244). Grants to AP that funded independent parts of the study originated from the Spanish Association Against Cancer (AECC; grant PROYE19040POST_001), Olga Torres Foundation (biannual grant A-2019/2020), Catalan Agency for Management of University and Research Grants (AGAUR) (grants 2017-SGR-1174 and 2021-SGR-01328), and the Spanish State Research Agency (AEI) of the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-116338RB-I00) as part of MICINN’s National Scientific and Technical Research and Innovation 2021-2023 Plans, which are cofinanced by the EUC-ERDF. The salaries of both EST and IV were funded by a Miguel Servet contract (reference MS13/00200) and a grant (CPII18/00022) from ISCIII to EST. LP was funded by the AECC (project GCTRA16015SEDA). YC is the recipient of a doctoral scholarship from the China Scholarship Council (202008440322). BG was financed by the 2020-1.1.6-JÖVŐ-2021-00013 and 2020-4.1.1-TKP2020 grants of the Ministry for Innovation and Technology in Hungary. LSM is the recipient of a doctoral scholarship from the University Lecturer Training (FPU) Program (FPU14/06217) of the Spanish Ministry of Universities. AEC’s salary is covered by grant PT17/0009/0019 from ISCIII (MICINN, cofunded by the ERDF) to CNAG-CRG.